San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

H.C. Wainwright reiterated its Buy rating and $110 price target for Maze Therapeutics (MAZE) after KOL calls validated the HORIZON Phase 2 dataset, confirming the drug’s efficacy in different patient cohorts. The data provides a clear path to pivotal trials, suggesting separate non-diabetic and diabetic arms with distinct endpoints. Analysts also noted the potential long-term advantages of MZE829 over competitors and anticipate that upcoming data from Vertex Pharmaceuticals’ AMPLIFIED trial could further validate the APOL1 inhibition mechanism.